Product Description
Mechanisms of Action: Carbohydrate Metabolism Cofactor, Amino Acid Metabolism Cofactor, Cholesterol Absorption Cofactor, Glutamine Synthetase Cofactor, GT Cofactor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Brazil | Ecuador | Egypt | Hong Kong | Indonesia | Ireland | Jordan | Korea | Malaysia | New Zealand | Spain | Taiwan | Turkey | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: American Regent, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05661682 |
TE20001 | P4 |
Withdrawn |
Other |
2025-10-31 |
2025-02-13 |
Primary Endpoints |
|
NCT05677126 |
TE20002 | P4 |
Withdrawn |
Other |
2024-08-01 |
2024-11-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/21/2026 |
News Article |
Electric Metals (USA) Limited Announces Grant of Deferred Share Units |
|
10/24/2025 |
News Article |
Electric Metals (USA) Limited Closes $4 Million Non-Brokered Private Placement |
|
10/23/2025 |
News Article |
Electric Metals Announces Private Placement Offering |
|
10/06/2025 |
News Article |
Electric Metals Files NI 43-101 Preliminary Economic Assessment for the North Star Manganese Project on SEDAR+ |